The European Commission has authorized XOLREMDI® (mavorixafor) as the first treatment for WHIM syndrome in the European Union.

Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union USA – English USA – English Approval follows a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) EC approval… #Europe #EU #EuropeanUnion #NorgineB.V. https://www.europesays.com/europe/26231/

Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union | Corporate Norgine B.V. / Key word(s): Product Launch/Miscellaneous Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first… #Europe #EU #European https://www.europesays.com/europe/26244/

Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union Approval follows a posi… #Europe #EU #EuropeanCommission #(Mavorixafor) #CXCR4receptor #EuropeanMedicinesAgency #exceptionalcircumstances #hypogammaglobulinemia #marketingauthorisation #Norgine #Patients #pharmaceuticalcompany #primaryimmunodeficiency #WHIMsyndrome #whitebloodcells https://www.europesays.com/europe/26264/